ArticleCell death & disease2025
Targeting the SMAD3/CISD2 axis suppresses bladder cancer progression by promoting ferroptosis in mesenchymal-like bladder cancer cells.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The poor prognosis of bladder cancer (BCa) is primarily attributed to the acquisition of invasive and metastatic capabilities by tumor cells through epithelial-mesenchymal transition (EMT), yet the dynamic alterations in ferroptosis during EMT and their regulatory mechanisms remain unelucidated. This study is the first to reveal the mechanism by which the Smad3/CISD2 signaling axis regulates ferroptosis in mesenchymal-like bladder cancer cells. Clinical sample analysis demonstrated significantly reduced expression of E-cadherin and upregulation of N-cadherin and Vimentin in muscle-invasive bladder cancer tissues (MIBC), with EMT-related marker levels correlating with overall survival rates in BCa patients. In TGF-β1-induced mesenchymal-like bladder cancer cells, ferroptosis-related genes (GPX4, SLC7A11) were markedly elevated, alongside increased lipid peroxides (LPO) and glutathione (GSH) levels. However, mesenchymal-like bladder cancer cells exhibited heightened sensitivity to the ferroptosis inducer Erastin, showing more pronounced suppression of proliferation, elevated ROS, higher LPO and MDA levels, and reduced GSH, confirming their enhanced susceptibility to ferroptosis. RNA-seq revealed significant downregulation of Smad3 in ferroptosis inducer treated mesenchymal-like bladder cancer cells. Smad3 knockdown further exacerbated ferroptosis markers (elevated Fe²⁺, ROS, LPO; decreased GSH), inhibited migration, invasion, and proliferation-phenotypes reversible by ferroptosis inhibitors. Mechanistically, ChIP-seq combined with RNA-seq demonstrated that Smad3 regulates CISD2 expression by binding its promoter region, with clinical specimens confirming a positive correlation between Smad3 and CISD2 expression. Functional rescue experiments showed that CISD2 overexpression in Smad3-knockdown mesenchymal-like bladder cancer cells reversed abnormal increases in Fe²⁺, ROS, LPO, and MDA while restoring GSH levels, indicating that Smad3 modulates ferroptosis through a CISD2-dependent pathway. In vivo experiments further demonstrated that targeting the Smad3/CISD2 axis significantly suppressed xenograft tumor growth and activated ferroptosis. In conclusion, this study elucidates a novel mechanism by which the Smad3/CISD2 axis dynamically regulates ferroptosis through redox homeostasis reprogramming during EMT, providing a potential therapeutic strategy for targeting the progression of MIBC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.